Arvinas (ARVN) Change in Accured Expenses (2017 - 2026)
Arvinas' (ARVN) quarterly Change in Accured Expenses came in at -$6.8 million in Q1 2026, down 750.0% year-on-year from $1.0 million in Q1 2025, and down 142.5% quarter-over-quarter from $16.0 million in Q4 2025.
Arvinas (ARVN) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Arvinas' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$6.8 million for Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 750.0% year-over-year to -$6.8 million in Q1 2026; TTM through Mar 2026 was -$7.7 million, a 22.22% decrease from a year earlier, with the FY2025 full-year figure at -$1.7 million, up 91.98% from the prior year.
- Change in Accured Expenses retreated to -$6.8 million in Q1 2026 per ARVN's latest filing, from $16.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $25.2 million in Q4 2022 and bottomed at -$16.8 million in Q2 2025.
- The 5-year median for Change in Accured Expenses is -$100000.0 (2025), against an average of $458823.5.
- Across the five-year window, Change in Accured Expenses jumped 3750.0% in 2022 and slumped 1033.33% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at $25.2 million in 2022, then tumbled by 94.84% to $1.3 million in 2023, then slumped by 476.92% to -$4.9 million in 2024, then soared by 426.53% to $16.0 million in 2025, then slumped by 142.5% to -$6.8 million in 2026.
- Per Business Quant, the three latest ARVN Change in Accured Expenses figures stand at -$6.8 million (Q1 2026), $16.0 million (Q4 2025), and -$100000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | -6.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.80 Mn |
| Mar 31, 2026 | -6.80 Mn |
| Dec 31, 2025 | 16.00 Mn |
| Dec 31, 2025 | 16.00 Mn |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -16.80 Mn |
| Jun 30, 2025 | -16.80 Mn |
| Mar 31, 2025 | -800,000.00 |
| Mar 31, 2025 | -800,000.00 |
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Dec 31, 2023 | 1.30 Mn |